Ovarian cancer is the fifth commonest cause of cancer death in European women. The majority of patients present with advanced disease for which the treatment is surgery followed by chemotherapy. Platinum-containing chemotherapy regimens have become the standard first-line treatment in advanced disease but although the majority of patients experience an objective clinical response less than 20% of patients experience long term disease-free survival (Cannistra, 1993) . At relapse, second-line treatment with platinum-based regimens can produce useful palliation. In these circumstances the response rate is dependent on the duration of response to first-line platinum (Gore et al., 1990; Markman et al., 1991) . In the majority of patients tumours eventually become refractory to platinum treatment and response to other conventional agents is unusual.
Paclitaxel is an antimitotic agent derived from the bark of Taxus brevifolia (pacific yew tree) which acts by stabilising and promoting microtubule assembly (Schiff et al., 1979) . Responses to paclitaxel in ovarian cancer were shown in 1989 when McGuire et al. (1989) reported a 25% response rate in patients with persistent or refractory epithelial ovarian cancer. Other reports of activity followed and the overall response rate for 189 patients in five studies was 29% (19-40%), with durable responses of more than 1 year in some patients. Many of these patients had tumours resistant to platinum-based chemotherapy (Einzig et al., 1989 (Einzig et al., , 1992 Thigpen et al., 1990; Sarosy et al., 1992) .
Owing to the widespread perception of possible benefit that paclitaxel may provide, a protocol was designed for compassionate treatment of patients with refractory or recurrent disease following platinum and other therapies. The entry criteria were deliberately permissive with regard to previous treatment in an attempt to reflect more accurately commonly encountered clinical situations. 
Patients and methods
The study was initiated in the UK and Eire in August 1992 and 11 centres participated. Patients aged between 18 and 75 with histologically proven epithelial carcinoma of the ovary or fallopian tube with measurable disease were eligible. Eligibility criteria included: (1) prior treatment with at least one platinum containing regimen but a maximum of three previous chemotherapy regimens; (2) Eastern Cooperative Oncology Group (ECOG) performance status 0-2; (3) absolute neutrophil count (ANC) >2.0 x I091-1, platelet count > 100 x I091'; (4) adequate renal and hepatic function (creatinine <1.5 times upper normal limit, total bilirubin <1.25 times upper normal limit); (5) no significant cardiac history (myocardial infarction within the past 6 months; second-or third-degree heart block, congestive heart failure or atrial/ventricular arrhythmias). Data on treatment-free interval was not available in two patients (responders/total number of patients) situation are low and depend on the interval between the end of the previous treatment and start of the phase II study (Blackledge et al., 1989) . Patients who progress on primary treatment or relapse within 6 months of primary treatment have a particularly poor prognosis and most of the patient population studied here fall into this category. Eighty-five per cent of our patients had multiple sites of disease, often bulky and their median time since last chemotherapy was short at 92.5 days with 97 patients (63%) having a treatment-free interval of less than 6 months. A response rate of 16% in this group therefore compares favourably with response rates of 10% or less seen with other phase II agents (Blackledge et al., 1989) . It is also of interest that the response rate did not vary with treatment-free interval, or the number of previous platinum regimens (Table I) . Ninety-five patients (61%) had been treated with two or three chemotherapy regimens and in fifty-four patients these had all been platinum containing. A response rate of 15% in this group is encouraging as is the response rate of 17% in patients with tumours refractory to platinum. The duration of response in patients with recurrent ovarian cancer who respond to salvage therapy is in the order of 4-7 months (Thigpen et al., 1993) . The median duration of response (275 days or 9 months with a 1 year survival rate of 35%) again compares favourably. The results from this study are consistent with those of Trimble et al. (1993) who showed that in a group of heavily pretreated patients (having undergone three or more prior chemotherapy regimens) with recurrent tumour within 3 months, treatment with paclitaxel resulted in a 21% response rate.
Toxicity is a major issue in the development of new therapies for relapsed or platinum-resistant ovarian cancer since treatment is essentially palliative. In this report there were no treatment-related deaths and although WHO grade 3 and 4 toxicities were encountered they only rarely resulted in serious complications for the patient. Almost half of the patients experienced grade 3 or 4 neutropenia but only 4% had grade 3 or 4 thrombocytopenia. The duration of neutropenia was very short with recovery nearly always complete at day 21 and only six patients (4%) required a dose reduction. Patients receiving more than three prior chemotherapy regimens were given the lower dose of paclitaxel in order to minimalise possible haematological toxicities. However, the median neutrophil nadir for this group, 1.46 x IO 1'-(range 0.1-4.7) compared with 0.9 x 109 1-(range 0.0-8.5) in the 175 mg m-2 group suggests that these patients could tolerate the higher dose. Hypersensitivity reactions were well controlled by premedication and only five patients had treatment delayed because of this complication. Less than 20% of patients had grades 3 or 4 nausea/vomiting or peripheral neuropathy and only 10% of patients withdrew from the study because of toxicity. The major toxicity in this study was alopecia, and this is a serious side-effect for any palliative treatment. However, when given as a 3 h infusion paclitaxel can be administered in the out-patient setting, and it was the experience of all investigators that patients tolerated treatment well. The duration of responses was short but no shorter than with other therapies and it remains to be seen whether or not paclitaxel improves survival and quality of life in this patient group. The activity of paclitaxel in a group of patients with a poor prognosis such as those studied here suggests that paclitaxel has a place as first-line chemotherapy in advanced epithelial ovarian cancer. One of the first studies to investigate this question (GOG11) compared cisplatin and paclitaxel (75 mg m2 and 135 mg m12) with cisplatin and cyclophosphamide (75 mg m-2 and 750 mg m-2) in patients with suboptimally debulked stage III and IV ovarian cancer. Initial results from 209 evaluable patients showed a greater response rate in the cisplatin/ paclitaxel arm (79% vs 63% P<0.01; McGuire et al., 1993) .
Median survival was also significantly improved in the cisplatin/paclitaxel arm (37.5 months vs 24.4 months cisplatin/cyclophosphamide P=0.0001:relative risk 0.59 for cisplatin/paclitaxel; McGuire et al., 1995). The cisplatin/ paclitaxel regimen showed greater toxicity in terms of neutropenia, fever, peripheral neurotoxicity and alopecia. However, this increase in toxicity was not reflected in discontinuations for adverse events (7% cisplatin/paclitaxel vs 6% cisplatin/cyclophosphamide) or the ability to administer treatment on schedule with the overall dose of cisplatin being equal in both arms. These are encouraging results and further studies to assess activity both as single agent and in combination are currently under way.
Paclitaxel is active in relapsed and platinum-resistant epithelial ovarian cancer, is well tolerated and can be given in the out-patient setting. It is a valuable addition to the treatment options available and can produce useful palliation with limited controllable toxicity. However, the prognosis for this group of patients as a whole remain poor.
